Zentalis Pharmaceuticals Inc (ZNTL)

$19.31

-0.55

(-2.77%)

Market is closed - opens 7 PM, 04 Oct 2023

Insights on Zentalis Pharmaceuticals Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 66.6% return, outperforming this stock by 79.6%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 155.7% return, outperforming this stock by 195.2%

Performance

  • $19.08
    $20.15
    $19.31
    downward going graph

    1.19%

    Downside

    Day's Volatility :5.31%

    Upside

    4.17%

    downward going graph
  • $15.55
    $31.46
    $19.31
    downward going graph

    19.47%

    Downside

    52 Weeks Volatility :50.57%

    Upside

    38.62%

    downward going graph

Returns

PeriodZentalis Pharmaceuticals IncSector (Health Care)Index (Russel 2000)
3 Months
-30.99%
-3.2%
0.0%
6 Months
10.41%
-2.7%
0.0%
1 Year
-13.02%
0.8%
-0.4%
3 Years
-44.91%
22.3%
14.9%

Highlights

Market Capitalization
1.9B
Book Value
$7.41
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-4.87
Wall Street Target Price
49.6
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-23.57%
Return On Equity TTM
-57.29%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-222.9M
Diluted Eps TTM
-4.87
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-4.82
EPS Estimate Next Year
-4.46
EPS Estimate Current Quarter
-1.04
EPS Estimate Next Quarter
-1.04

Analyst Recommendation

Buy
    94%Buy
    5%Hold
    0
    0%Sell
Based on 17 Wall street analysts offering stock ratings for Zentalis Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 17 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
16
16
16
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 156.86%

Current $19.31
Target $49.60

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Zentalis Pharmaceuticals Inc
Zentalis Pharmaceuticals Inc
-24.04%
10.41%
-13.02%
-44.91%
-16.77%
Moderna, Inc.
Moderna, Inc.
-5.74%
-34.14%
-17.98%
43.27%
454.19%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-1.77%
-1.68%
9.3%
33.59%
106.18%
Novo Nordisk A/s
Novo Nordisk A/s
-7.65%
10.71%
66.6%
150.37%
305.83%
Seagen, Inc.
Seagen, Inc.
2.57%
3.72%
52.7%
4.95%
167.21%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-0.89%
9.77%
14.81%
28.32%
82.99%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Zentalis Pharmaceuticals Inc
Zentalis Pharmaceuticals Inc
NA
NA
NA
-4.82
-0.57
-0.24
0.0
7.41
Moderna, Inc.
Moderna, Inc.
34.44
34.44
0.0
-3.45
0.07
0.01
0.0
44.49
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
21.94
21.94
9.01
41.82
0.19
0.1
0.0
225.94
Novo Nordisk A/s
Novo Nordisk A/s
43.71
43.71
2.03
1.66
0.82
0.22
0.01
2.52
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-3.52
-0.26
-0.13
0.0
13.96
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
27.05
27.05
0.41
14.71
0.25
0.16
0.0
60.01
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Zentalis Pharmaceuticals Inc
Zentalis Pharmaceuticals Inc
Buy
$1.9B
-16.77%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$39.3B
454.19%
34.44
11.33%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$88.8B
106.18%
21.94
33.93%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$411.7B
305.83%
43.71
33.4%
Seagen, Inc.
Seagen, Inc.
Hold
$39.7B
167.21%
NA
-33.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$89.1B
82.99%
27.05
35.4%

Institutional Holdings

  • Matrix Capital Management Company, LLC

    19.77%
  • FMR Inc

    14.98%
  • Eventide Asset Management, LLC

    9.74%
  • Vanguard Group Inc

    6.98%
  • BlackRock Inc

    5.60%
  • State Street Corporation

    4.47%

Corporate Announcements

  • Zentalis Pharmaceuticals Inc Earnings

    Zentalis Pharmaceuticals Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

developing potentially best-in-class, novel small molecules targeting fundamental biological pathways in cancer

Organization
Zentalis Pharmaceuticals Inc
Employees
156
CEO
Dr. Kimberly Lynn Blackwell M.D.
Industry
Health Technology

FAQs